Non-tuberculous mycobacterial infections in solid organ transplant recipients: An update  by Abad, Cybele L. & Razonable, Raymund R.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 4 (2016) 1–8 
Contents lists available at ScienceDirect 
Journal of Clinical Tuberculosis and Other 
Mycobacterial Diseases 
journal homepage: www.elsevier.com/locate/jctube 
Non-tuberculous mycobacterial infections in solid organ transplant 
recipients: An update 
Cybele L. Abad ∗, Raymund R. Razonable 
Division of Infectious Diseases and the William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, 55905 MN, 
United States 
a r t i c l e i n f o 
Article history: 
Received 2 November 2015 
Revised 5 April 2016 
Accepted 8 April 2016 
Keywords: 
Mycobacteria 
Transplantation 
Pneumonia 
Lung transplantation 
Drug interactions 
a b s t r a c t 
Non-tuberculous mycobacteria are ubiquitous environmental organisms that are now increasingly recog- 
nized as important causes of clinical disease in solid organ transplant recipients. Risk factors of non- 
tuberculous mycobacteria infection are severe immunologic defects and structural abnormalities. Lung 
transplant recipients are at higher risk for non-tuberculous mycobacterial disease compared to recipi- 
ents of other solid organs. The clinical presentation could be skin and soft tissue infection, osteoarticular 
disease, pleuropulmonary infection, bloodstream (including catheter-associated) infection, lymphadeni- 
tis, and disseminated or multi-organ disease. Management of non-tuberculous mycobacteria infection is 
complex due to the prolonged treatment course with multi-drug regimens that are anticipated to interact 
with immunosuppressive medications. This review article provides an update on infections due to non- 
tuberculous mycobacteria after solid organ transplantation, and discusses the epidemiology, risk factors, 
clinical presentation, and management. 
© 2016 The Authors. Published by Elsevier Ltd. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). 
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2. Introduction 
Non-tuberculous mycobacteria (NTM) consist of over 140 dis-
inct species of ubiquitous environmental organisms that are often
ound in soil and water. NTMs are generally considered uncom-
on causes of clinical disease in the general population. However,
TM disease appears to be increasingly reported. In a population-
ased epidemiologic study in the United States, the incidence of
kin and soft tissue disease due to NTM increased from 0.7 per
0 0,0 0 0 population during 1980–1999 to 2.0 per 10 0,0 0 0 popula-
ion during 20 0 0–20 09 [1] . NTM infections after solid organ trans-
lantation (SOT) are also perceived to have increased in frequency
n recent years, reﬂecting increased exposure, increased length of
urvival, and improved methods for diagnosis [2] . Among all SOT
opulations, lung transplant recipients are at higher risk for NTM
isease for several possible reasons, such as the direct exposure
f the transplanted lung to the environment, and structural abnor-
alities in lung transplant recipients may interfere with host de-
enses against inhaled organisms. The increased risk of NTM dis-
ase in these patients may also be a reﬂection of the severity of
mmunologic deﬁciencies, given that lung transplantation is asso-∗ Corresponding author. 
E-mail address: razonable.raymund@mayo.edu (C.L. Abad). 
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405-5794/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article uiated with a more intense degree of immune suppression than
ther types of organ transplantation [3] . 
Although relatively rare in incidence compared to other post-
ransplant infections, recognizing diseases due to NTM is impor-
ant, as delays in diagnosis may lead to poor outcomes. Manage-
ent of these NTM infections is also frequently complex due to
he prolonged treatment course and the anticipated drug–drug in-
eractions between antimycobacterial drugs and the immunosup-
ressive medications. 
This review article will provide an update on the literature of
TM infections after SOT, and discuss the epidemiology, risk fac-
ors, clinical presentation, and management in the context of organ
ransplantation. 
. Epidemiology 
The epidemiology of NTM infections in SOT recipients is not
ully deﬁned. Its incidence is diﬃcult to determine with certainty
s reporting of disease is not mandatory, and the ubiquitous na-
ure of these organisms makes it hard to determine whether or
ot NTM species isolated from non-sterile source are clinically rel-
vant. Conservation studies have isolated NTM from both natural and
otable water sources [4] –[7] . For example, Mycobacterium xenopi
nd M. kansasii are common in man-made water systems while M.
arinum is linked to aquatic environments and is often called “ﬁshnder the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). 
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t  tank granuloma” [8] , [9] . Often, the differentiation between coloniza-
tion and clinical disease is diﬃcult. 
There is also evidence to suggest that nosocomial transmission of
NTM is increasing, and results in conditions ranging from harmless
colonization to invasive infection. These hospital-borne infections are
usually more common among patients undergoing surgery, those on
hemodialysis, or have immune suppressed conditions [5] . To date, only
a few cases have been reported among SOT recipients [10] . 
The epidemiology among transplant recipients varies widely
based on geography and type of transplantation [11] . Hence, the
incidence can only be estimated based on available case series
and anecdotal reports. Among renal transplant recipients, the es-
timated incidence of NTM infections is between 0.16% and 0.55%
[12–20] . Slightly higher incidence rates are reported in heart trans-
plant recipients (2.8%) [21] and lung transplant recipients (0.46
to 4.4%) [22–25] . For some unclear reason, NTM infections among
liver transplant recipients have not been systematically reported,
but the estimated incidence rate is comparatively low at 0.04%
[15] . We have found no reported cases of NTM infections among small
bowel, composite tissue, and pancreatic transplants. 
The frequency and types of speciﬁc NTM infections, and the
causative species varies by the type of organ transplant. To date,
there have been more than 20 different species reported to
cause disease in transplant recipients. Interestingly, Mycobacterium
kansasii is the most commonly reported NTM among heart trans-
plants [2] . Rapidly growing mycobacteria (RGM) are reported less
frequently among SOT recipients than hematopoietic stem cell
transplants (HSCT) recipients. Among SOT recipients with NTM in-
fection, RGM were reported in approximately 40% of renal trans-
plants and 10% of heart and lung transplant recipients [11] . 
3. Risk factors 
Among the risk factors that have been associated with NTM dis-
ease, in general, include immunocompromised states (such as ac-
quired immunodeﬁciency syndrome), treatment with monoclonal
antibody therapies (e.g., targeting tumor necrosis factor- α), and
genetic defects of the interferon-gamma receptors and signaling
pathways [26] . Structural lung disease from chronic obstructive
pulmonary disease (COPD), cystic ﬁbrosis, and bronchiectasis have
also conferred increased risk of NTM disease [27,28] . For similar
reasons, SOT recipients may be at increased risk of NTM disease
due to immunologic and structural abnormalities. 
First, the immunosuppressive drug regimens (or the net state
of immune-suppression) may promote the progression to clinical
disease among those with environmental exposures (or those colo-
nized with NTM), with a higher risk among those with augmented
immunosuppression, such as those treated for acute or chronic
cellular rejection [29] . To our knowledge, however, no studies have
speciﬁcally looked at rate of progression and no particular immuno-
suppressive drug is associated with a higher risk for NTM. 
Second, the disruption of mucocutaneous barriers (during
surgery or the need for vascular access catheters) may serve as
portals of entry for NTM. Third, structural abnormalities may
promote airway colonization and disease, particularly among lung
transplant recipients with impaired mucociliary clearance. Patients
with cystic ﬁbrosis, for example, are often colonized or infected
with NTM prior to transplantation. For most patients, this does not
preclude transplantation, but patients have to undergo prolonged
treatment even after organ transplantation [30] . It is very likely
that other additional host-immune or structural local factors are
involved in the development of NTM disease, but these have yet
to be identiﬁed [24] . 
A case-control single-center study by Longworth et al.
[3] sought to identify clinical and demographic risk factors asso-
ciated with NTM disease in the transplant population. During aeriod of 7 years, they identiﬁed 34 SOT recipients with NTM dis-
ase, and the majority (71%)were male, with a median age of 54
ears. Slightly over half of the cases (54%) occurred among lung
ransplant recipients. NTM disease developed relatively early, af-
er a median of 8 months (IQR: 2–87 months), after transplanta-
ion. There was wide diversity in the causative species, but M. ab-
cessus was the most common, followed by M. avium complex . The
ites of infection also varied from pleuropulmonary disease, to cu-
aneous and deep tissue, intra-abdominal, and disseminated infec-
ions. Univariate analysis identiﬁed lung transplant recipients are
t highest risk (OR 11.49, p < 0.01) and having developed biopsy-
roven acute rejection also signiﬁcantly increased the risk (OR 4,
 < 0.03) of NTM disease. The results of this study validates the
heory that structural abnormalities, exposure of the transplanted
ung to potential environmental pathogens, and the advanced state
f immune suppression in lung transplant recipients all contribute
o the higher risk of NTM infection. 
. Clinical presentation 
The clinical manifestations of NTM infections in SOT recipients
re usually protean in nature. Accordingly, establishing the diag-
osis may be diﬃcult based on clinical symptoms alone. Hence,
linicians should have a high index of suspicion and a low thresh-
ld to obtain diagnostic specimens for mycobacterial culture. The
ost common clinical presentation of NTM disease among SOT
ecipients is cutaneous or osteoarticular in nature [2] . In general,
TM disease can be classiﬁed into one of six categories – pleuro-
ulmonary, skin and soft tissue (including those with secondary
issemination), musculoskeletal (osteoarticular), bloodstream (in-
luding catheter-associated), lymphadenitis, and disseminated or
ulti-organ disease. Data on the isolates and clinical presentations
rom these cases are included in Table 1. 
.1. Lung transplant 
Lung transplant recipients are unique among SOT recipients be-
ause they are often colonized with NTM prior to transplantation
ue to structural damage from underlying pulmonary disease. In
act, lung recipients who have a history of colonization with M.
bscessus often develop progression to clinical disease after trans-
lantation, despite adequate anti-mycobacterial therapy. As such,
olonization with multi-drug resistant NTM prior to transplanta-
ion is considered a relative contraindication to lung transplanta-
ion by some centers [30–32] . 
Not surprisingly, the most common site of NTM disease af-
er transplantation is pleuropulmonary [3,23,24,30,32–36] , with M.
bscessus as the most commonly isolated species, followed by
AC. These patients with pulmonary NTM disease often present
ith chronic productive cough, shortness of breath, pleuritic pain,
nd/or fever and chills [23,34] . CT scan ﬁndings are variable but
lassically show nodular or tree-in-bud ﬁndings [23] . 
Although pulmonary disease is by far the most com-
on presentation, NTM infections in lung transplant recipients
ay present as disseminated [3,24,31,32,34,36–41] , osteoarticular
24,30,37] , and cutaneous [3,34,42] disease. 
.2. Non-lung transplant 
.2.1. Kidney 
Among the SOT population, kidney transplant recipients have
he most reported number of NTM infections with a total of 148
ases to date [3,9,10,12–20,36,43–121] . This is likely due to the rel-
tively large numbers of kidney transplants performed, compared
o other SOT. The most common manifestation among these pa-
ients is local cutaneous disease including cases with secondary
C.L. Abad, R.R. Razonable / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 4 (2016) 1–8 3 
Table 1 
Clinical presentation of NTM disease in solid organ transplant recipients. 
Type of 
transplant 
Reference Patients 
( n ) 
Gender 
M/F 
Age, median 
(yr) 
Median time 
to onset (mos) 
Mycobacterium species Type of infection 
Lung 
Lung [3,23–25,30–35,37–42, 
150–155] 
102 48/35 42.2 13.3 MAC, 26; M. abscessus, 59; M. 
hemophilum, 4; M. fortuitum, 2 
M. marinum, 2; M. kansasii, 2; 
M. asiaticum, 1; M. chelonae, 3 
MAC + Abscessus, 1; M. simiae, 1 
M. genavense, 1 
Pleuropulmonary, 65 
Cutaneous, 11 
Osteoarticular, 9 
Disseminated, 17 
Other, 0 
Non-lung 
Kidney [3,9,10,12–20,36,43–121] 148 87/53 45 27 MAC, 15; M. gordonae, 4; 
NTM NOS, 14; M. xenopi, 7 
M. chelonae, 31; M. abscessus, 9 
M. fortuitum, 12; M. haemophilum, 
13 
M. kansasii, 24; M. genavense,7 
M. scrofulaciecum, 2; 
M. immunogenum, 1;M. marinum, 6 
M. gastri,1; M. terrae, 1; Mult, 1 
Pleuropulmonary, 23 
Cutaneous, 51 
Cutaneous, with 
dissemination, 5; 
Osteoarticular, 31; 
Disseminated, 22; 
Other, 16 
Heart [21,53,96,107,135–149] 33 25/5 47 33 M. kansasii, 9; MAC, 8; M. 
hemophilum,5; M. scrofulaceum, 1; 
M. chelonae, 2; M. theroresistibile,2 
NTM NOS, 2; M. fortuitum, 1; 
M. genavense, 3 
Pleuropulmonary, 6 
Cutaneous, 9 
Cutaneous with 
dissemination, 4 
Osteoarticular, 3 
Disseminated, 11 
Liver [3,53,76,96,122–134] 21 5/12 51 24 MAC, 7; M. xenopi, 1; M. chelonae, 1 
M. abscessus, 3; M. hemophilum, 2 
M. genavense, 2; M. marinum, 1 
M. llatzerense,1; M. mucogenicum, 1 
M. triplex,1; Mult, 1 
Pleuropulmonary, 7 
Cutaneous, 4 
Cutaneous with dissem, 
2 
Osteoarticular, 2 
Disseminated, 4 
Other, 2 
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2  utaneous dissemination, followed by osteoarticular disease. Cu-
aneous NTM disease often manifests as painless, violaceous nodules
hat may ulcerate and commonly follow a sporotrichoid appearance.
he most common NTM species is M. chelonae, followed by M.
ansasii. 
.2.2. Liver 
To date, there are only 21 cases of NTM reported among liver
ransplant recipients [3,53,76,96,122–134] , despite the increasing
olume of liver transplantations. The underlying reason for the
arity of NTM cases among liver transplant cases is not known.
mong all cases reported, the most common clinical presentations
ere pleuro-pulmonary followed by cutaneous disease. In general,
hose with pleuro-pulmonary disease presented with cough, fever or
hills, shortness of breath, or a combination thereof. MAC was the
ost common species isolated, accounting for one-third of all isolates.
.2.3. Heart 
Like liver transplant recipients, NTM disease among heart trans-
lant recipients appears to be rare. There have only been a to-
al of 33 cases reported in the literature [21,53,96,107,135–149] . M.
ansasii was the most frequently isolated NTM species, and 39%
13/33) cases presented with cutaneous disease, half of which had
econdary dissemination. 
. Diagnosis 
.1. Clinical diagnosis 
The diagnosis of NTM disease in transplant recipients is often
iﬃcult. Establishing a diagnosis of pulmonary infection, especially
mong lung transplant recipients, can be challenging because NTM
solates recovered from sputum samples may represent coloniza-
ion. Given the diagnostic dilemma, the American Thoracic Society
ATS) published guidelines on the diagnosis and treatment of dis-
ase due to NTM [27] . A combination of clinical, radiographic, and
acteriologic criteria is required for diagnosis of NTM pulmonaryisease ( Table 2 ). Similarly, extrapulmonary disease is diagnosed
hrough a combination of clinical and microbiologic ﬁndings with
r without adjunctive histologic conﬁrmation. 
Since NTM infections are rare, they are not often included in
outine diagnostic testing. Hence, a high level of clinical suspicion
or NTM disease is essential for rapid and accurate diagnosis. Fre-
uently, time to clinical presentation from transplantation can be
ong, with a median of 13.3 months among lung transplant pa-
ients [23–25,31–35,37–42,150–155] , and even longer (range of 24–
3 months) among other SOT recipients. Since the infection may
ccur at any time, NTM disease has to be considered with any
nexplained febrile illness, surgical site or bone infection, non-
ealing wound or cutaneous lesion, or pleuropulmonary disease,
specially when routine bacterial cultures are non-diagnostic. Of-
en, the ﬁrst indication of an NTM disease is the absence of bacte-
ial growth on routine cultures. In these instances, and whenever
here are suspicious lesions in a transplant recipient, clinical sam-
les and tissues should be obtained for histologic and microbio-
ogic examination. Often, repeated sampling may be necessary to
stablish the diagnosis. It is important to emphasize that although
ranulomas on histopathology are suggestive of possible NTM dis-
ase, the absence of granulomatous lesions does not necessarily
egate the diagnosis in transplant recipients who have attenuated
mmune responses. 
.2. Laboratory diagnosis 
To conﬁrm the clinical suspicion of NTM disease, clinical
amples should be sent to the microbiology laboratory for acid
ast staining, mycobacterial cultures, and histopathology. The
aboratory should be informed that NTM is a clinical considera-
ion in order to guarantee proper media selection, temperature
ncubation, and duration of culture growth. Some NTM species are
astidious organisms and have speciﬁc growth requirements. For
xample, M. haemophilum and M. marinum both grow best between
8–30 °C . However, M. haemophilum requires media supplemented
4 C.L. Abad, R.R. Razonable / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 4 (2016) 1–8 
Table 2 
Clinical and microbiologic criteria for diagnosing nontuberculous mycobacterial lung disease [27] a . 
Clinical (both required) 
1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or a high-resolution computed tomography scan that shows multifocal bronchiectasis 
with multiple small nodules (A, I) a 
AND 
2. Appropriate exclusion of other diagnoses (A, I) 
Microbiologic 
1. Positive culture results from at least two separate expectorated sputum samples (A, II). If the results from (1) are nondiagnostic, consider repeat sputum AFB 
smears and cultures (C, III). 
OR 
2. Positive culture result from at least one bronchial wash or lavage (C, III) 
OR 
3. Transbronchial or other lung biopsy with mycobacterial histopathologic features (granulomatous inﬂammation or AFB) and positive culture for NTM or biopsy 
showing mycobacterial histopathologic features (granulomatous inﬂammation or AFB) and one or more sputum or bronchial washings that are culture positive for 
NTM (A, II) 
OTHER 
4. Expert consultation should be obtained when NTM are recovered that are either infrequently encountered or that usually represent environmental contamination 
(C, III) 
5. Patients who are suspected of having NTM lung disease but do not meet the diagnostic criteria should be followed until the diagnosis is ﬁrmly established or 
excluded (C, III) 
6. Making the diagnosis of NTM lung disease does not, per se, necessitate the institution of therapy, which is a decision based on potential risks and beneﬁts of 
therapy for individual patients (C, III) 
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gwith iron-containing compounds such as ferric ammonium citrate,
hemin, or hemoglobin, while M. genavense requires mycobactin [27] . 
The Interferon Gamma Rapid Assays (IGRAs) are not useful in the
diagnosis of NTM. However, is important to know that the target anti-
gens used ( e.g. ESAT-6 and CFP-10) which are present in M. tuberculo-
sis, are also present in some other mycobacteria, including M. kansasii
and M. marinum. As such, there is some cross-reactivity. The diagnos-
tic usefulness of the IGRAs has not been validated for NTM, however,
and they are not recommended for diagnoses [156] , [157] . 
Identiﬁcation of the NTM to the species or subspecies level is
necessary for epidemiologic, prognostic and therapeutic considera-
tions. In referral laboratories, speciation may be accomplished by
molecular probes and 16S rDNA sequencing [27] . Knowledge of the
NTM species is necessary for choosing an empiric regimen. In addi-
tion, determination of the antimycobacterial susceptibilities of cer-
tain NTM species is recommended to guide the ﬁnal targeted an-
timycobacterial therapy. 
6. Treatment 
A detailed review of the treatment regimens used for speciﬁc
NTM disease is beyond the scope of this review article, and the
ATS guideline is available for reference [27] . Nevertheless, some
key features of treatment of NTM disease among SOT recipients
merit emphasis. First, asymptomatic colonization is often not treated
prior to transplantation or re-transplantation. However, in patients
who are symptomatic, with a high burden of organism, such as in
CF patients colonized with NTM, one basic tenet is to try and reduce
mycobacterial burden prior to transplantation, and to continue to
treat aggressively during the immediate period after transplantation
[158] . Duration of treatment is inﬂuenced by the offending pathogen
and drug tolerability. Second, whenever possible, reduction of
immunosuppression should be considered among SOT recipients
to aid in the clearance of infection and/or minimize drug inter-
actions. Third, other contributing factors, such as concomitant
viral infections (in particular, CMV infection) should be treated.
[2] Fourth, the choices of antimicrobial drugs for treatment are
similar to those recommended for non-immunosuppressed pa-
tients. However, interactions between medications for NTM and
the immunosuppressive agents are anticipated. The rifamycins,
which are the backbone for treating some NTMs such as MAC, are
potent cytochrome P450 (CYP450) inducers and will expectedly
reduce the blood levels of calcineurin and mammalian target of
rapamycin (mTOR) inhibitors. If the dose of these drugs are notdjusted accordingly when rifamycins are initiated, it may lead to
ubtherapeutic levels and could lead to allograft rejection. Com-
ared to Rifampin, Rifabutin is a less potent inducer of CYP450,
nd is the preferred agent for treatment among transplant recip-
ents. In contrast, the macrolide antibiotic such as Clarithromycin
s a potent CYP450 inhibitor, and could have the reverse effect.
zithromycin has minimal in vitro inhibitory effect on CYP450 and
s the preferred macrolide for the transplant population. Often, a
ombination of a macrolide and rifamycin is needed for treatment,
nd thus, the level of calcineurin inhibitors should be monitored
losely and drug doses adjusted accordingly. 
In general, combination antimycobacterial therapy for a pro-
onged period of time is the rule for treatment of NTM disease.
ore than one active agent is necessary for treatment to avoid in-
erval development of resistance during therapy. In patients with
evere or disseminated disease and high organism burden, a min-
mum of 3 active drugs should be considered for induction treat-
ent, followed by de-escalation to dual treatment during mainte-
ance therapy. Often, treatment is continued until there is documen-
ation of multiple negative cultures. 
The choice of antimycobacterial agents and duration of ther-
py are largely dependent on the speciﬁc NTM isolate, given the
ide variability of in vitro susceptibility patterns. Although recom-
endations exist for treatment duration for speciﬁc diseases due
o NTM, this is often considered minimum duration of treatment
mong transplant recipients, as response to treatment in this pop-
lation of patients is often delayed, and microbiologic cures are
iﬃcult to achieve. This prolonged exposure to a variety of drugs
lso leads to signiﬁcant toxicity, which is heightened in this popu-
ation of patients. 
There are also other interventions that should complement
tandard anti-NTM medical therapy. In addition to reducing im-
unosuppression, one should advocate for timely surgical resec-
ion, debridement of ﬂuid collections or devitalized tissue, or re-
oval of infected devices in order to decrease organism bioburden
nd reduce the risk of drug resistance. In cases where devices cannot
e safely removed, prolonged suppressive therapy, usually with multi-
le oral agents, if feasible, is recommended. 
The use of secondary prophylaxis for NTM infections in the
ransplant population remains controversial. If selected, it should
e based on available susceptibility data and discussed in detail
ith experts in treating such infections in complex patients. 
A summary of treatment recommendations based on existing
uidelines for selected NTM species is provided in Table 3. 
C.L. Abad, R.R. Razonable / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 4 (2016) 1–8 5 
Table 3 
Treatment regimens for selected NTM species in transplant recipients. 
Organism Recommended regimen Alternative/second line drugs Duration Other 
SGM 
M. avium complex AZM 250–500 mg/d + RFB 
300 mg/d + EMB 15 m/k/d ±AMK IV 
RIF, CLR, AMK, MXF 12 mos of negative sputum 
cultures (for pulmonary dse) 
M. kansasii RFB 300 mg, EMB15m/k/d, INH 
5/m/k/d + Pyridoxine 50 mg/d 
If with RIF resistance-3 drug 
regimen based on in-vitro 
susceptibilities 
AZM, MXF, SXT, STR 12 mos of negative sputum 
cultures (for pulmonary dse) 
M. marinum Two active agents, usually 
AZM + EMB 
RIF/RFB,CLR, EMB, DOX 3–4 mos Uniformly resistant to 
INH/PZA 
RGM 
M. abscessus Must be based on in-vitro 
susceptibility data: 
AZM 250 mg/d plus IV (AMK, FOX, 
IPM) 
LZD, TGC Linezolid, tigecycline 4–6 mos Uniformly resistant to 
anti-TB drugs 
M. chelonae Must be based on in-vitro 
susceptibility data: 
AZM plus (1) other agent (TOB, 
LZD, IPM) 
AMK, DOX, CIP 4–6 mos 
M. fortuitum At least 2 active agents with in vitro 
activity 
AMK, CIP, SXT, FOX, IPM, AZM, 
DOX 
12 mos of negative sputum 
cultures (for pulmonary dse) 
4-6 mos for SSTI or 
bone-joint 
Inducible resistance to MAC 
Fastidious NTM 
M. haemophilum No standardized susceptibility data AMK, AZM, CIP, RIF, RFB, Not determined Uniformly resistant to EMB 
M. genavense AZM + at least one other active agent AMK, RFB/RIF, CIP, AZM, STR Not determined EMB with limited activity 
M. gordonae Must be based on in-vitro 
susceptibility data 
EMB, RFB, AZM, LZD, CIP Not determined Most frequently isolated 
contaminant 
AZM – Azithromycin, RFB – Rifabutin, AMK – Amikacin, CLR- Clarithromycin, MXF – Moxiﬂoxacin, SXT – Trimethoprim-sulfmethoxazole, STR – Streptomycin, FOX – Cefoxitin, 
IPM – imipenem, LZD – Linezolid, TGC – tigecycline, DOX – Doxycycline, CIP – ciproﬂoxacin, MAC – macrolides, PZA – Pyrazinamide. 
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The prognosis of NTM disease in transplant recipients is highly
ariable, due to multiple factors including type of transplant, im-
une suppression, site and extent of NTM infections, and the spe-
iﬁc NTM species. Overall, there is a high rate of treatment failure,
s detailed below. Prognosis is worse, and may lead to death, par-
icularly among SOT patients with disseminated disease. 
.1. Lung transplant recipients 
Among the 102 cases of NTM infection in lung transplant re-
ipients, information regarding outcomes are available among 79
atients [25,30–32,35,37–40,42,150,152–155] . Of these, 33 were re-
orted to have been cured, cleared of infection, or culture negative
t the end of treatment; 11 had some improvement, 3 had recur-
ence, while 7 had either no response or minimal response. Death
ccurred in 25 patients, with mortality attributed to NTM among
 patients with either pleuropulmonary or disseminated disease;
otably, 7 of 8 deaths were from M. abscessus ; the remaining one
rom M. genavense . 
There were 2 recent series that looked speciﬁcally at M. ab-
cessus [30,32] : among the 5 patients reported by Qvist, 1 patient
leared the infection, 2 patients were clinically well despite persis-
ently positive cultures, while 2 died but due to non-NTM related
auses. Outcomes of patients in the study by Lobo were slightly
etter, with 3 patients clearing the infection, and 1 with death re-
ated to disseminated M. abscessus . 
.2. Non-lung transplant recipients 
.2.1. Kidney 
Among all cases of renal transplant recipients with NTM dis-
ase, data regarding outcome was available for 124/148 cases
9,10,12,16–18,20,43–52,54–80,82–114,116–121] . Sixty two percent 77/124) reported cure with initial therapy, and 14 (11%) had
onsiderable improvement during ongoing treatment. However, 
0 (8%) had disease recurrence, and 3 (2%) had persistent or
rogressive disease requiring either change in medical manage-
ent and/or surgical intervention. Disease recurrence or persis-
ence was associated with either osteoarticular or cutaneous dis-
ase, although there was no predominant NTM species. There were
 deaths (6%) attributed to NTM-disease [12,17,45,73,76,95] . All
eaths with the exception of one [80] was from disseminated dis-
ase; the underlying NTM species causing disseminated NTM infec-
ion was varied, and included M. kansasii, M. fortuitum, MAC , and
. genavense. 
.2.2. Liver 
Of the 21 cases of NTM in liver transplant recipients, out-
ome was reported for 17 of them [53,76,96,122–134] . Outcome
as favorable in most liver recipients, with the majority of pa-
ients (11/17) being cured, or having disease improvement by the
ime of follow up (1/17). Death occurred in 4 cases, but only one
as attributed to disseminated NTM disease, from M. genavense
nfection [53] . 
.2.3. Heart 
Among heart transplant recipients, outcome was reported on 17
ases [21,53,96,107,136–145,147–149] . Of these, 8 were cured, 1 im-
roved on treatment, and 3 had either recurrence or progression of
isease. Of the ﬁve deaths, three were attributed to disseminated
isease from NTM [21,107,145] , of varying species ( M. genavense ,
AC, and NTM not speciﬁed). 
. Conclusion 
NTM disease among transplant patients remains infrequent,
lthough its incidence appears to be increasing. This most likely
eﬂects improvement in microbiological techniques and im-
roved survival from transplantation. Although NTM infection is a
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 relatively uncommon, the risk of NTM disease is many-fold greater
in transplant recipients than in the general population. 
Among all transplant recipients, lung transplant recipients are
more prone to develop NTM disease, although it is more commonly
reported among kidney recipients, likely due to the higher volume
of kidney transplants. 
The clinical presentation of NTM disease in the transplant pop-
ulation is protean in nature, and can be very diﬃcult to diagnose,
both clinically and microbiologically. It differs substantially from
NTM disease associated with HIV-AIDS, which is more often than
not disseminated MAC. In the transplant population, the clinical
presentation varies depending on the underlying transplant, and
can be insidious in nature. The treatment regimen for NTM disease
in transplant patients is the same as in the non-transplant popu-
lation, although it is often more complicated given potential drug–
drug interactions between antimycobacterial and immunosuppres-
sive agents. 
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